

Identity:

Title: Professor, MD, PhD, DMSci, FHFA
 Family Name(s): Gustafsson
 First Name(s): Finn
 Age: 55 years

Photo:**Application for the following position in the HFA Board or Nominating Committee:**

Coordinator of the Clinical Science Section

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	Rigshospitalet, University of Copenhagen
Department:	Cardiology
Address:	9 Blegdamsvej, Copenhagen
Post code / Zip:	2100
Country:	Denmark

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

Consultant cardiologist, Rigshospitalet
 Medical Director Advanced HF, transplantation and MCS

Education

MD, University of Copenhagen 1994. Specialist in Cardiovascular Medicine, 2007.
 Postgraduate training in Copenhagen and Toronto, Canada.
 Ph.D. University of Copenhagen 2000.

Research

Papers listed in PubMed: 466.
 H-index: 64 (Scopus), 73 (Google scholar)
 ORCID: 0000-0003-2144-341X

Senior Guest Editor (Guest editor-in-chief) *Circulation: Heart Failure* (2022-)
 Associate editor *European Journal of Heart Failure* (2020-2022)
 Associate editor for *Circulation: Heart Failure* (2017-21)
 Associate editor for *International Journal of Cardiology* (2010-16).
 Manuscript reviewer for: *NEJM, JAMA, EHJ, Circulation, JACC*.

Invited lectures at > 200 international scientific meetings.
 On the steering committee of several international trials and registries.

Scientific supervision

Supervised 13 phd projects. Currently phd supervisor for 8 phd students.

Other

Scientific advisor, European Medicines Agency, London.

Grant reviewer: Scottish Government Health Directorates, British Heart Foundation, Australian Government Frontier Research.

External assessor (promotions) at Harvard Medical School and University of Glasgow

Selected recent papers:

Mirza KK, Szymanski M, Schmidt T, de Jonge N, Brahmabhatt D, Billia P, Hsu S, MacGowan GA, Jakovljevic D, Agostoni P, Tomabara F, Jorde U, Rochlani Y, Vandersmissen K, Reiss N, Russell SD, Meyns B, **Gustafsson F**: Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)

JACC: Heart Failure 2021; 9: 758-767.

Westin O, Fosbøl EL, Maurer MS, Leicht BP, Hasbak P, Mylin AK, Rørvig S, Lindkær TH, **Gustafsson F**: Screening for cardiac amyloidosis 5-15 years after surgery for bilateral carpal tunnel syndrome – The CACTUS study.

JACC 2022; 80: 967–977.

Gustafsson F, Damman K, Nalbantgil S, Van Laake LW, Tops LT, Thum T, Adamopoulos S, Bonios M, Coats ASJ, Crespo-Leiro MG, Mehra M, Filippatos G, Hill L, Metra M, Jankowska E, de Jonge N, Kaye D, Masetti M, Parissis J, Milicic D, Seferovic P, Rosano G, Ben Gal T: Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the HFA of the ESC.

Eur J Heart Fail 2023; 25: 457-468.

Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, **Gustafsson F**, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WH, Yu WC, Obici L, Simões M, Fernandes M, Hvitfeldt Poulsen S, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD: Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.

NEJM 2023; 389: 1553-1565.

Mehra MR, Netuka I, Uriel N, Katz JN, Pagani FD, Jorde UP, **Gustafsson F**, Connors JM, Ivak P, Cowger J, Ransom J, Bansal A, Takeda K, Agarwal R, Byku M, Givertz MM, Bitar A, Hall S, Zimpfer D, Vega JD, Kanwar MK, Saeed O, Goldstein DJ, Cogswell R, Sheikh FH, Danter M, Pya Y, Phancao A, Henderson J, Crandall DL, Sundareswaran K, Soltesz E, Estep JD: Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial.

JAMA 2023;330:2171-2181.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

Board member HFA of the ESC 2020-2024

Member of the HFA Committee on Advanced HF 2018-24 (co-chair 2022-2024)

Course director HFA course on Advanced HF (2023-24)

Co-Chair HFA Clinical Practice Update Course (2022-23)

Faculty member PCHF courses in Zurich and London (2017-)

Faculty HFA Exam preparatory course

Author and co-author of 16 HFA consensus documents. Reviewer for the 2021 ESC guidelines on HF.

Nucleus member and web editor of the Working group for Pharmacotherapy of the ESC (2007-10)

Chairman Working Group for HF Danish Society of Cardiology (2016-2017)

Member of the ESC Peripartum Cardiomyopathy (PPCM) Registry

Associate editor *European Journal of Heart Failure* (2020-22)

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

As coordinator for the clinical science section (CSS) I believe I can contribute positively to the HFA and the HFA community. The committees and working groups are a backbone of the HFA. Not only are consensus documents crafted in these groups, but ideas and input to the Board for other activities often originate from the committees. I have significant experience from my work in the Board and on the advanced HF committee to take on the role as coordinator of the CSS which I can hopefully further develop. An area where the committees and working groups may improve is greater involvement of volunteers not (currently) represented in the groups. I believe it is important to engage the next generation of HF specialists and volunteers from all HFA regions in the groups. Promoting that would be one important aim for me, should I be offered the role as coordinator.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

I currently hold a position with 50 % clinical work (HF) and 50 % dedicated to research and related activities. That leaves sufficient flexibility for me to take on the task as coordinator for the CSS and to dedicate the time required to work in the HFA Board executive committee. At the same time, I would step down as chair of the advanced HF committee.